home / stock / th:cc / th:cc news

TH:CC News and Press, Theratechnologies Inc. From 02/21/24

Stock Information
Company Name: Theratechnologies Inc.
Stock Symbol: TH:CC
Market: TSXC
Website: theratech.com
Menu
TH:CC TH:CC Quote TH:CC Short TH:CC News TH:CC Articles TH:CC Message Board
Get TH:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
TH:CC - Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022 Record quarterly revenue of $23.5 million and annual revenue of $81.8 million Updated Phase 1 tri...
TH:CC - Expected Canadian Company Earnings on Wednesday, February 21st, 2024

B2Gold Corp. (BTO:CA) is expected to report $0.11 for Q4 2023 North American Construction Group Ltd. (NOA:CA) is expected to report $0.82 for Q4 2023 DREAM Unlimited Corp. Class A Subordinate Voting Shares (DRM:CA) is expected to report for Q4 2023 Whitecap Resources Inc. (WCP:CA) is ...

TH:CC - Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell killing, in triple-negative breast cancer xenograft model Weekly administration of single agent sudocetaxel zendusortide demon...

TH:CC - Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biop...
TH:CC - Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...

TH:CC - Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

FDA requesting clarifications around chemistry, manufacturing and controls and additional information related to immunogenicity CRL does not impact commercial availability of EGRIFTA SV ® , the F4 formulation of tesamorelin, the only medication approved in the U.S. ...

TH:CC - Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application

FDA continues to review the file past the Prescription Drug User Fee Act goal date of January 22, 2024 MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company ...
TH:CC - Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

Trogarzo ® IM maintenance dosing aims to further enhance the convenience of non-oral therapy for heavily treatment-experienced adults with HIV Submission comes on the heels of the recent FDA approval of the Trogarzo ® IV push loading dose MONTREAL...

TH:CC - Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement

Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement Canada NewsWire MONTREAL , Dec. 21, 2023 /CNW/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company ...

TH:CC - Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose

Updated label means new Trogarzo ® patients no longer require initiation of treatment by 30-minute infusion Complete IV push method enables easier and more convenient administration of Trogarzo ® for heavily treatment-experienced adults with HIV M...
Previous 10 Next 10